九芝堂股份有限公司 2021 年第三季度报告 证券代码：000989 证券简称：九 芝 堂 公告编号：2021-061 九芝堂股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------------------|--------------------------|------------- ...

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2021-058 九芝堂股份有限公司 关于参加 2021 年湖南辖区上市公司 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈 述或者重大遗漏负连带责任。 为进一步加强与投资者的互动交流，九芝堂股份有限公司（以下简称"公 司"）将参加由湖南证监局主办，湖南省上市公司协会与深圳市全景网络有限公 司协办的 "2021 年湖南辖区上市公司投资者网上集体接待日"活动，现将有关 事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台，采取网络远程的方式举行，投资者可以登陆"全景·路演天下"网站 （http://rs.p5w.net）参与公司本次投资者网上集体接待日活动，活动时间为 2021 年 9 月 24 日（星期五）15:00－17:00。 届时，公司财务总监、董事会秘书、证券事务代表等相关人员将参加本次活 动，通过网络在线交流形式与投资者进行沟通。欢迎广大投资者积极参与。 特此公告。 九芝堂股份有限公司董事会 2021 年 9 月 18 日 九芝堂股份有限 ...

九芝堂股份有限公司 2021 年半年度报告全文 九芝堂股份有限公司 2021 年半年度报告 2021-047 2021 年 08 月 1 九芝堂股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资 者的实质承诺，请投资者注意投资风险。 公司已在本报告"第三节、管理层讨论与分析"中分析了公司未来发展可能 面临的风险因素和应对措施。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 九芝堂股份有限公司 2021 年半年度报告全文 目录 | --- | --- | |---------------------------------|------------------------------- ...

九芝堂股份有限公司 2021 年第一季度报告全文 九芝堂股份有限公司 2021 年第一季度报告 公告编号：2021-034 2021 年 04 月 1 九芝堂股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证季度报告中财务报表的真实、准确、完整。 2 九芝堂股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------|------------------|--------------------------| | ...

Financial Performance - The company's operating revenue for 2020 was ¥3,559,540,963.73, representing an increase of 11.81% compared to ¥3,183,694,789.58 in 2019[25] - The net profit attributable to shareholders for 2020 was ¥272,309,874.61, a 41.72% increase from ¥192,146,815.99 in 2019[25] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥250,004,429.28, up 62.79% from ¥153,577,965.77 in 2019[25] - The basic earnings per share for 2020 was ¥0.3242, reflecting a 42.13% increase from ¥0.2281 in 2019[25] - The total revenue for the year 2020 was CNY 3,559,540,963.73, representing an increase of 11.81% compared to CNY 3,183,694,789.58 in 2019[100] - The company’s net profit for 2020 was CNY 272,309,874.61, with distributable profits amounting to CNY 526,294,567.09[172] - The total distributable profit for the year was CNY 1,384,106,673.77, indicating strong financial performance[172] - The company reported a significant increase in profits, with a 174.85% increase in net profit compared to the previous year[172] Assets and Liabilities - The total assets at the end of 2020 were ¥5,071,508,340.80, a 3.40% increase from ¥4,904,747,670.66 at the end of 2019[25] - The net assets attributable to shareholders at the end of 2020 were ¥3,922,517,553.92, a decrease of 1.60% from ¥3,986,459,014.73 at the end of 2019[25] - The company reported a significant decrease in accounts receivable, down to ¥392,372,555.44, which is 7.74% of total assets, due to enhanced collection efforts[124] - The total cash dividend distributed was CNY 342,376,804.80, representing 100% of the profit distribution[174] - The cash dividend per 10 shares was CNY 4.00, with a total share base of 855,942,012 shares after deducting treasury shares[174] Cash Flow - The net cash flow from operating activities for 2020 was ¥609,555,035.41, down 28.40% from ¥851,290,910.78 in 2019[25] - The company reported a loss of ¥75,254,511.13 from investment income, representing -21.42% of total profit, mainly due to amortization and losses from the acquisition fund investment in Stemedica[121] - Operating cash inflow totaled ¥4,293,744,054.00, a slight increase of 0.24% year-on-year, while operating cash outflow rose by 7.34% to ¥3,684,189,018.59[117] - The net increase in cash and cash equivalents was ¥497,351,816.93, a significant improvement of 324.71% compared to the previous year[120] Research and Development - The company has over 200 valid patents related to pharmaceuticals and health products, showcasing its commitment to innovation and R&D[56] - Research and development expenses increased by 11.28% to approximately ¥113.42 million, primarily due to increased investment in stem cell research projects[114] - The company is actively advancing the development of new drugs and enhancing its research capabilities, including projects related to stem cells and anticoagulants[155] - The company has established multiple technology platforms, including a postdoctoral research station and a national enterprise technology center, to support its R&D efforts[56] Market and Sales - The company has established a sales network across the country, utilizing both self-operated and agency sales models, and is actively exploring e-commerce and modern sales channels[49] - The company has seen significant growth in sales of its key products compared to the previous year, reflecting effective market strategies and product focus[61] - Six product varieties generated sales revenue exceeding CNY 100 million, with An Gong Niu Huang Wan sales increasing by 44% and Shu Xue Tong injection sales rising by 14.54% year-on-year[62] - The revenue from traditional Chinese medicine reached CNY 2,609,135,994.49, accounting for 73.30% of the main business revenue, with a year-on-year growth of 12.94%[96] Strategic Initiatives - The company plans to distribute a cash dividend of ¥4 per 10 shares to all shareholders[7] - The company has implemented a cultural marketing strategy that integrates traditional Chinese medicine promotion, enhancing its brand presence across various medical institutions and pharmacies[55] - The company is committed to building a diversified health industry ecosystem, enhancing its internet hospital services, and optimizing resource allocation[156] - The company is implementing a strategy of internal growth and external expansion to enhance its core value capabilities and establish a health ecosystem management system[153] Risk Management - The company has identified potential risks and countermeasures in its future development strategy[6] - The company faces risks related to drug price reductions due to procurement processes influenced by medical insurance pressures, and it aims to maintain price stability through quality improvements and brand value enhancement[160] - The company is addressing potential risks from raw material supply shortages and price fluctuations by strengthening market monitoring and strategic reserves[161] - The company acknowledges the uncertainties in drug research and development due to stricter regulations and aims to control risks through adherence to national policies and effective project management[162] Corporate Governance - The company has committed to ensuring the independence of its financial operations and governance structure[180] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[180] - The company has implemented a comprehensive budget management and strategic goal management approach to support its operational efficiency and decision-making processes[157] - The company has not made any adjustments to its profit distribution policy during the reporting period, adhering strictly to its established guidelines[168]

九芝堂股份有限公司 2020 年第三季度报告全文 九芝堂股份有限公司 2020 年第三季度报告 2020-092 2020 年 10 月 1 九芝堂股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证季度报告中财务报表的真实、准确、完整。 2 九芝堂股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|-------------------------------|-------------------------|------------------|----- ...

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2020-088 九芝堂股份有限公司关于参加湖南辖区上市公司 2020 年度投资者网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈 述或者重大遗漏负连带责任。 为进一步加强与投资者的互动交流，九芝堂股份有限公司（以下简称"公司"） 将参加由中国证券监督管理委员会湖南监管局、湖南省上市公司协会与深圳市全 景网络有限公司联合举办的"湖南辖区上市公司 2020 年度投资者网上集体接待 日"活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台，采取网络远程的方式举行，投资者可以登陆"全景·路演天下"网站 （http://rs.p5w.net/）参与公司本次投资者网上集体接待日活动，活动时间为 2020 年 9 月 11 日（星期五）下午 15:00－17:00。 届时，公司董事会秘书等相关人员将参加本次活动，通过网络在线交流形式 与投资者进行沟通。欢迎广大投资者积极参与。 特此公告。 九芝堂股份有限公司董事会 2020 年 9 月 9 日 九芝堂股份 ...

九芝堂股份有限公司 2020 年半年度报告全文 九芝堂股份有限公司 2020 年半年度报告 2020-080 2020 年 08 月 1 九芝堂股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告涉及的未来计划、发展战略等前瞻性描述，不构成公司对投 资者的实质承诺，请投资者注意投资风险。 公司已在本报告"第四节、经营情况讨论与分析"中分析了公司未来发展可 能面临的风险因素和应对措施。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 九芝堂股份有限公司 2020年半年度报告全文 目录 | --- | --- | |-------|-------------------------------------------------------- ...

Financial Performance - The company's operating revenue for 2018 was ¥3,162,109,003.02, a decrease of 16.73% compared to ¥3,797,212,593.87 in 2017[23]. - Net profit attributable to shareholders was ¥336,479,563.54, down 52.76% from ¥712,254,464.85 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was ¥259,377,306.53, a decline of 60.55% from ¥657,536,899.41 in 2017[23]. - The basic and diluted earnings per share were both ¥0.39, down 52.44% from ¥0.82 in 2017[23]. - The weighted average return on equity decreased to 7.52% at the end of 2018 from 16.49% at the end of 2017, a drop of 8.97%[26]. - Total assets decreased by 10.65% to ¥5,247,929,616.49 from ¥5,873,723,167.38 in 2017[26]. - The net assets attributable to shareholders decreased by 4.52% to ¥4,297,879,781.66 from ¥4,501,439,851.05 in 2017[26]. - The company reported a government subsidy of ¥87,825,035.03 in 2018, compared to ¥51,923,353.60 in 2017, indicating an increase in non-recurring gains[30]. - The company reported a net profit of 1,481,444,433.10 RMB for 2018, with a cumulative undistributed profit of 1,123,169,654.08 RMB available for distribution[143]. Cash Dividend and Profit Distribution - The company plans to distribute a cash dividend of 4.00 CNY per 10 shares (including tax) to all shareholders based on the total share capital after deducting repurchased shares[6]. - The cash dividend for 2018 represents 103.35% of the net profit attributable to ordinary shareholders, which is 336,479,563.54 RMB[140]. - The total cash dividend, including other methods such as share buybacks, amounts to 540,039,632.93 RMB, accounting for 100% of the profit distribution[143]. - The cash dividend payout ratio for 2017 was 48.82%, with a total cash dividend of 347,741,694.40 RMB[140]. - The company has not proposed any stock bonus for the 2018 fiscal year, maintaining a focus on cash dividends[139]. - The cash dividend distribution is based on the total share capital of 869,354,236 shares, adjusted for any repurchased shares[139]. - The company is in a growth phase and aims to maintain a minimum cash dividend ratio of 20% in future distributions[143]. - The cash dividends for 2018 are expected to be distributed after the equity registration date, which will reflect the actual number of shares after buybacks[139]. Business Operations and Strategy - The company has not experienced any changes in its main business since its listing[21]. - The company has outlined potential risks and countermeasures in its business outlook section of the report[6]. - The company is a leading player in the traditional Chinese medicine sector, with over 300 product approvals across various therapeutic areas[49]. - The company has established a new research and development base project to enhance its innovation capabilities[48]. - The OTC product sales strategy includes the launch of upgraded oral liquid products, contributing to improved pricing power and profitability[55]. - The company has expanded its retail chain to 283 stores by the end of 2018, maintaining a strong position in the Chinese pharmacy market[57]. - E-commerce sales have improved profitability, with the company adopting an O2O model and launching products on platforms like JD.com and Meituan[60]. - The company is actively exploring modern sales channels, including e-commerce and micro-businesses, to enhance market reach[47]. - The company has implemented strategic adjustments in its prescription drug sales, focusing on terminal control and marketing model innovation[56]. - The company is focusing on expanding its prescription drug sales by enhancing its competitive capabilities and exploring new market opportunities[120]. Research and Development - The company invested in Stemedica, a U.S. company focused on stem cell research, which impacted the performance due to significant R&D expenditures leading to losses[29]. - The company completed 2,441 clinical observations and data collection for the study on the efficacy of Shuxuetong injection in preventing acute embolic stroke recurrence[62]. - The LFG project received over ¥10 million in project funding support and added 2 new authorized invention patents during the reporting period[61]. - The company applied for a total of 34 patents during the year, with 22 patents granted, including 14 invention patents[63]. - The company is actively conducting new drug research and development, with a focus on the LFG project, aiming for IND submissions in China and the U.S.[124]. - The company is advancing a stem cell project with a focus on technology transfer and clinical application, aiming for commercialization[127]. Corporate Governance and Compliance - The company has committed to maintaining financial independence, including having an independent financial department and accounting system, and ensuring no misuse of funds or assets[153]. - The company has made commitments to reduce and regulate related party transactions, ensuring fairness and compliance with market standards[152]. - There were no non-operating fund occupations by the controlling shareholder or related parties during the reporting period[157]. - The company has undergone changes in accounting policies in accordance with relevant standards, which are detailed in the report[158]. - The company has not experienced any significant accounting errors requiring retrospective restatement during the reporting period[159]. - The company is committed to ensuring that all assets are fully owned and independent, maintaining a complete governance structure[153]. - The company has pledged to avoid any competition with its controlling shareholder and related parties[152]. - The company’s financial personnel are independent and do not hold concurrent positions in related parties[153]. Market and Industry Outlook - The pharmaceutical industry is expected to maintain stable growth due to rising income levels and an aging population, with increased demand for traditional Chinese medicine[116]. - The company recognizes the challenges and opportunities presented by ongoing reforms in the pharmaceutical industry, positioning itself to leverage both traditional brand effects and innovative products[117]. - The pharmaceutical business segment continues to stabilize wholesale scale and develop a sales system centered on chain companies, with a focus on franchise development[123]. Subsidiaries and Investments - The company established a new subsidiary, Zhanjiang Jiuzhitang Traditional Chinese Medicine Clinic Co., Ltd., with a registered capital of 3 million yuan, in which the company holds a 51% stake[161]. - The company has established a joint venture, Huixian City Jiuzhitang Traditional Chinese Medicine Clinic Co., Ltd., with a registered capital of RMB 1.34 million, in which the company holds 51% equity[162]. - The company set up a wholly-owned subsidiary, Mudanjiang Jiuzhitang Youbo Health Technology Co., Ltd., with a registered capital of RMB 10 million, focusing on the production and sales of various pharmaceutical forms and health products[162]. - The company established another wholly-owned subsidiary, Beijing Jiuzhitang Health Management Center Co., Ltd., with a registered capital of RMB 10 million, providing health management and consulting services[162]. - The company co-founded Jiuzhitang (Shanghai) Life Science Co., Ltd. with a registered capital of RMB 10 million, focusing on technology development in the pharmaceutical and biotechnology sectors[162].

九芝堂股份有限公司 2017 年年度报告全文 证券代码：000989 证券简称：九芝堂 公告编号：2020-049 九芝堂股份有限公司 2017 年年度报告 2020 年 05 月 1 九芝堂股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资 者的实质承诺，请投资者注意投资风险。 公司已在本报告"第四节、经营情况讨论与分析"中分析了公司未来发展可 能面临的风险因素和应对措施。 公司经本次董事会审议通过的利润分配预案为：以总股本 869354236 股为 基数，向全体股东每 10 股派发现金红利 4.00 元（含税），送红股 0 股（含税）， 不以公积金转增股本。 2 九芝堂股份有限公司 2017 年年度报 ...